GlaxoSmithKline K.K. and National University Corporation Kyushu University have signed a strategic partnership agreement.

This collaboration will see GSK regularly sharing information with Kyushu University Hospital, with a special focus on oncology, a field where the hospital has a strong track record. The core objective of this partnership is to expedite the development of new medicines. Both parties will work together to devise early clinical trial strategies, launch trials, and streamline patient enrollment, ultimately speeding up drug development.

Koji Todaka, Director of the ARO Next Generation Medical Center at Kyushu University Hospital, said, "Our hospital's first basic policy is to provide advanced medical care and promote research and development. It is the university hospital's endeavor to conduct high-quality clinical trials as the final stage of development, including corporate clinical trials and physician-initiated clinical trials. Our recent partnership with GSK, a global company aiming for simultaneous development and simultaneous filing worldwide, coupled with our hospital's extensive track record, will be a great opportunity to deliver new treatments to patients. We hope that this will create a synergistic effect.”

Commenting on the partnership agreement, Izuru Miyoshi, General Manager of GSK's Medical Development Division, said, “GSK aims to bring positive changes to the health of more than 2.5 billion people by 2030.This collaboration with Kyushu University, which has extensive knowledge in the oncology field, will enable us to speed up clinical trials. We are confident that this is possible. Furthermore, we hope that this partnership will help improve drug lag/drug loss and evolve the clinical trial environment in Japan."